Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Mar 27, 2025; 17(3): 100820
Published online Mar 27, 2025. doi: 10.4240/wjgs.v17.i3.100820
Retrospective analysis of preoperative tumor marker levels in rectal cancer patients: Implications for diagnosis
Ming Li, Da-Hao Yuan, Zhi Yang, Teng-Xiang Lu, Lei Zhang
Ming Li, Da-Hao Yuan, Zhi Yang, Clinical Laboratory, Linquan County People’s Hospital, Linquan 236400, Anhui Province, China
Teng-Xiang Lu, Hemodialysis Center, Linquan County People’s Hospital, Linquan 236400, Anhui Province, China
Lei Zhang, Department of Gastrointestinal Surgery, Linquan County People’s Hospital, Linquan 236400, Anhui Province, China
Author contributions: Li M and Yuan DH conceptualized this study; Yang Z and Yuan DH contributed to data collection; Zhang L and Lu TX drafted the initial manuscript and contributed to formal analysis; Li M, Yang Z, and Zhang L provided guidance for this study and contributed to the methodology and visualization; Lu TX and Yang Z validated the study; and all the authors participated in this study and jointly reviewed and edited the manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Linquan County People’s Hospital (No. LQYY-2023-132).
Informed consent statement: The requirement for informed consent was waived because of the retrospective nature of the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No other available data.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lei Zhang, Associate Chief Physician, Department of Gastrointestinal Surgery, Linquan County People’s Hospital, No. 206 Jianshe South Road, Linquan 236400, Anhui Province, China. zlmale8902@sina.com
Received: December 13, 2024
Revised: January 20, 2025
Accepted: February 7, 2025
Published online: March 27, 2025
Processing time: 72 Days and 16.6 Hours
Abstract
BACKGROUND

Early detection of rectal cancer poses significant challenges. Current diagnostic methods, including colonoscopy, imaging techniques, and fecal tests, have limitations such as invasiveness, cost, and varying sensitivity. This study evaluated the diagnostic value of preoperative serum tumor markers in rectal cancer patients.

AIM

To investigate the value of a multi-marker approach for the preoperative diagnosis of rectal cancer.

METHODS

A retrospective analysis of 250 patients diagnosed with rectal cancer between July 2022 and July 2024 was conducted. Preoperative alpha-fetoprotein levels, carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), CA19-9, CA15-3, and CA72-4 were analyzed. All blood samples were collected under standardized conditions, including fasting status and proper storage methods, within two weeks before surgery. Diagnostic performance was assessed using receiver operating characteristic curve analysis. Correlations among clinicopathological features were also evaluated.

RESULTS

CEA demonstrated the highest diagnostic performance among individual tumor markers with an area under the curve (AUC) of 0.78 [95% confidence interval (CI): 0.73-0.83]. However, a combination of CEA, CA19-9, and CA72-4 showed superior performance, achieving an AUC of 0.87 (95%CI: 0.83-0.91). Significant correlations were observed between CEA levels and several clinicopathological features, including tumor stage (P < 0.001), lymph node involvement (P = 0.002), and distant metastasis (P < 0.001). Furthermore, in a subgroup analysis of patients diagnosed after July 2022, the integration of fecal occult blood testing with the tumor marker panel (CEA + CA19-9 + CA72-4) significantly improved diagnostic accuracy, increasing the AUC to 0.91 (95%CI: 0.86-0.96).

CONCLUSION

A multimarker approach combining CEA, CA19-9, and CA72-4 with fecal occult blood testing enhances the preoperative assessment of patients with rectal cancer. These findings suggest potential improvements in risk stratification and management of patients with rectal cancer.

Keywords: Rectal cancer; Tumor markers; Carcinoembryonic antigen; Cancer antigen 19-9; Cancer antigen 72-4; Fecal occult blood test; Diagnosis

Core Tip: This study highlights the effectiveness of a multi-marker approach for the preoperative diagnosis of rectal cancer. Analysis of serum levels of the tumor markers carcinoembryonic antigen, cancer antigen 19-9, and cancer antigen 72-4, along with fecal occult blood testing, demonstrated improved diagnostic accuracy, with an area under the curve of 0.91. Significant correlations between elevated carcinoembryonic antigen levels and clinicopathological features, such as tumor stage and lymph node involvement, suggest that this combined strategy could enhance the risk stratification and management of patients with rectal cancer, ultimately aiding in earlier detection and better clinical outcomes.